Full Press Release Details
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company s Annual
Meeting of Shareholders
Atlanta, GA., May 15, 2013 Galectin Therapeutics (NASDAQ: GALT) will host a conference call at
9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company s Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment
community on the Company s pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer.
Following his presentation, Dr. Traber will answer questions from shareholders present at the meeting. Shareholders not attending the meeting may submit questions in advance for
Dr. Traber s consideration; questions should be submitted via email to IR@galectintherapeutics.com no later than May 21, 2013.
The conference call and presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at
The audio portion of the call can also be accessed by dialing (888) 327-8914 (toll-free
within the United States) or (847) 944-7654 (toll, from outside the United States). The passcode for participants is 7827311#
in approximately 10 minutes before the event to ensure a timely connection.
The webcast will also be archived on the Company s website.
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the
Company s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and
efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at http://www.galectintherapeutics.com.
Dr. Harold H. Shlevin (678)-615-3213
Chief Operating Officer